Chorea Market: Increasing Awareness about Neurological Disorders Is Projected to Boost the Industry Growth at a Healthy CAGR of ~ 12.4% Forecast by 2022-2030

Pune, India, January 2022 /MRFR Press Release/- Market Research Future has a half cooked research report on the chorea market.

Market Highlights

Chorea is a nonrhythmic, rapid, nonsuppressible involuntary movement. Chorea is often worsened by anxiety, stress and subsides during sleep. It is also found that most patients attempt to disguise chorea by a purposeful activity. Sydenham’s chorea is the most common form of chorea in childhood, whereas Huntington’s disease, and drug induced chorea found mostly in adult onset cases.

A number of factor such as growing public awareness, and technological advancements, rising prevalence of neurological disorders, increasing awareness, improving regulatory framework, increasing government assistance, increasing adoption rate, and rising funding and reimbursement policies are propelling the growth of the global chorea market.

However, challenges in research and development, side-effects of treatment, cost of treatment, the presence of misbranded and spurious drugs and poor healthcare system in low and middle-income countries may hamper the growth of the market.

The Chorea Market is expected to reach USD 2,458.5 Million by 2030 at 12.4% CAGR during the forecast period 2022-2030.

Regional Analysis

The Americas dominate the chorea market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the chorea market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.

Asia Pacific is the fastest growing chorea market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.

The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.

Segmentation

The Global Chorea Market is segmented on the basis of type, treatment, and distribution channels.

On the basis of the type, the market is classified as Huntington’s disease, Rheumatic (Sydenham’s chorea), and Drug-induced chorea.

On the basis of the treatment, the market is classified as medical care, and surgical care. The medical care is further segmented into neuroleptics, dopamine-depleting agents, GABAergic drugs, coenzyme Q10, intravenous immunoglobulin, and plasmapheresis. The sub segments neuroleptic includes, typical neuroleptics, and atypical neuroleptics. The surgical care is further segmented into deep brain stimulation, and cell transplantation.

On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.

Explore In-depth Details: Chorea Market Research Report

Key Players

Some of key the players in the global chorea market are Teva Pharmaceutical Industries Ltd., Valeant, Medtronic, Alnylam Pharmaceuticals, Inc., Cyberonics, Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Boston Scientific Corporation, GlaxoSmithKline plc, Lundbeck, Prana Biotechnology Limited, Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, SOM Biotech, Raptor Pharmaceutical, Omeros, Ipsen, Pfizer, Palobiofarma, Aleva Neurotherapeutics SA, and others.